PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 28, 2026Kidney International Reports0 citationsOpen Access

Wcn26-9116 Efficacy of Pegcetacoplan in Patients With Lower Baseline Proteinuria: A Subgroup Analysis From the Valiant Trial

SHSeung Hyeok HanHKH J KangNWNicholas Webb

Key Result

Pegcetacoplan treatment for 52 weeks demonstrated consistent clinical efficacy and sustained benefit in adolescents, matching the overall VALIANT trial population.

Key Points

  • The study aims to evaluate the efficacy of pegcetacoplan in patients with lower baseline proteinuria.
  • Conducted a subgroup analysis from the VALIANT trial.
  • Evaluated clinical efficacy over a 52-week treatment period.
  • Included adolescents as a specific focus group.
  • Efficacy of pegcetacoplan was consistent with the overall VALIANT population.
  • Demonstrated sustained benefits over 52 weeks in treated adolescents.

Structured PICO

Does pegcetacoplan reduce proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria?

P
Population
Patients with C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) with baseline proteinuria ≤1.5 g/g
I
Intervention
Pegcetacoplan (subcutaneous infusion twice weekly)
C
Comparator
Placebo
O
Outcome
Change from baseline to Week 26 in log-transformed urine protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR)surrogate

Pegcetacoplan demonstrated clinically meaningful reductions in proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria (≤1.5 g/g).

Limitations

  • Post hoc analysis

Abstract

Conclusion: Clinical efficacy of 52 weeks of pegcetacoplan treatment for adolescents was consistent with the overall population of VALIANT, confirming its sustained benefit in broad patient populations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Han et al. (2026) studied this question. Pegcetacoplan treatment for 52 weeks demonstrated consistent clinical efficacy and sustained benefit in adolescents, matching the overall VALIANT trial population.

synapsesocial.com/papers/69c770418bbfbc51511e0723https://doi.org/10.1016/j.ekir.2026.106328
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1WCN26-6817 PROGNOSTIC VALUE OF ESTIMATED FUNCTIONAL NEPHRON NUMBER AT DIAGNOSIS IN MEMBRANOUS NEPHROPATHY: A LONGITUDINAL COHORT STUDY2026 · 1 citations
  2. 2Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN2026
  3. 3WCN24-683 EFFICACY OF 12-WEEK PEGCETACOPLAN IN KIDNEY TRANSPLANT RECIPIENTS WITH RECURRENT C3 GLOMERULOPATHY (C3G) OR IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)2024
  4. 4#1467 Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 12-week evolution2024 · 3 citations
  5. 5Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN2025 · 43 citations